Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?

Despite several clinical trials have assessed different agents in the adjuvant setting, renal cell carcinoma (RCC) still remains a disease orphan of an effective adjuvant treatment. In fact, systemic therapies targeting angiogenesis that have been observed to be effective in metastatic setting faile...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollica, Veronica, Rizzo, Alessandro, Di Nunno, Vincenzo, Santoni, Matteo, Cheng, Liang, Lopez-Beltran, Antonio, Scarpelli, Marina, Cimadamore, Alessia, Montironi, Rodolfo, Massari, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article on Update on Molecular Classification and Individualized Treatments of Genitourinary Tumors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039625/
https://www.ncbi.nlm.nih.gov/pubmed/33850792
http://dx.doi.org/10.21037/tau-20-1125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039625/
https://www.ncbi.nlm.nih.gov/pubmed/33850792
http://dx.doi.org/10.21037/tau-20-1125

Ejemplares similares